炎症
肿瘤微环境
癌症
癌症研究
免疫疗法
生物
免疫学
细胞因子
肿瘤坏死因子α
免疫系统
遗传学
作者
Noriho Iida,Amiran Dzutsev,Charles A. Stewart,Loretta Smith,Nicolas Bouladoux,Rebecca A. Weingarten,Daniel A. Molina,Rosalba Salcedo,Timothy Back,Sarah D. Cramer,Ren‐Ming Dai,Hiu Kiu,Marco Cardone,Shruti Naik,Anil K. Patri,Ena Wang,Francesco M. Marincola,Karen M. Frank,Yasmine Belkaid,Giorgio Trinchieri
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2013-11-21
卷期号:342 (6161): 967-970
被引量:2158
标识
DOI:10.1126/science.1240527
摘要
The Microbiota Makes for Good Therapy The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI